Zydus Lifesciences and CSIR-Central Drug Research Institute (CDRI) Lucknow are all set to develop best-in-class drug for Chronic Kidney Disease induced Osteoporosis. Chronic kidney disease (CKD) affects over 10% of the global population, posing significant health challenges. CKD causes a progressive loss of kidney function and can ultimately lead to kidney failure. One of the hallmarks of CKD is the disruption of mineral metabolism, increasing the risk of osteoporosis and fractures. Those above the age of 65, particularly women, are at higher risk. Unfortunately, most of the conventional anti-osteoporosis medications are contraindicated in patients with CKD, due to the risk of worsening renal function. Therefore, there is an urgent need to develop safe and effective drugs for osteoporosis that will reduce fracture risk without a deterioration of renal function.
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism. In patients with advanced stages of CKD and osteoporosis, Sclerostin levels are observed to be high. Based on research conducted at CDRI and data from antibody-based therapies (biologics), Sclerostin has emerged as a promising drug target for treating CKD-induced osteoporosis as well as postmenopausal osteoporosis. To develop oral medication through the discovery of small molecule inhibitors of Sclerostin, a collaborative research agreement was signed by Zydus Lifesciences, Ahmedabad and Central Drug Research Institute, Lucknow on September 17, 2024 at Zydus Research Centre, Ahmedabad. Under this agreement, CDRI and Zydus will jointly undertake preclinical research. Any drug candidate emerging from the efforts will be developed by Zydus for India and other markets.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1808.50 |
| Dr. Reddys Lab | 1342.45 |
| Cipla | 1472.45 |
| Lupin | 2147.55 |
| Zydus Lifesciences | 973.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
